Reported 8 months ago
Renew Pharmaceuticals (6696) announced that its subsidiary Belite's new drug Tinlarebant (also known as LBS-008) for treating juvenile Stargardt disease (STGD1) has been granted Sakigake Designation by the Japanese Ministry of Health, Labor and Welfare. This designation provides benefits to expedite the approval process, making it the only ophthalmic drug and non-Japanese developed candidate in the list. With clinical trials unfolding in 11 countries and favorable certifications from multiple agencies, Renew aims to become the first approved drug globally for STGD1, targeting the estimated $1.27 billion global market by 2030.
Source: YAHOO